See the DrugPatentWatch profile for azacitidine

Azacitidine, a medication commonly used to treat various types of blood cancer, has been investigated for its potential to reduce deaths related to graft-versus-host disease (GVHD). GVHD is a condition that can occur after a stem cell transplant, where the transplanted cells attack the recipient's body.

A study published in the journal Biology of Blood and Marrow Transplantation in 2018 found that azacitidine may help to reduce the severity of GVHD in mice [1]. The researchers suggested that azacitidine could be a potential therapeutic option for the treatment of GVHD in humans. However, more research is needed to confirm these findings and to determine the safety and efficacy of azacitidine for this indication in humans.

It is important to note that, as of the time of this writing, azacitidine has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of GVHD [2]. Further clinical trials will be necessary to establish the potential of azacitidine in reducing GVHD-related deaths.

In summary, while there is some evidence to suggest that azacitidine may have the potential to reduce the severity of GVHD and potentially reduce GVHD-related deaths, more research is needed before it can be considered a standard treatment option for this indication.

Sources:

1. Biology of Blood and Marrow Transplantation. (2018). Azacitidine ameliorates graft-versus-host disease by inducing regulatory T cells. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055333/>
2. DrugPatentWatch. (n.d.). Azacitidine. <https://www.drugpatentwatch.com/drugs/azacitidine>